After three years at the helm, NuVasive Inc. CEO Gregory Lucier will step down.
Lucier had worked with the San Diego-based medical device company since 2013. He will continue to serve as chairman of the board.
“Greg quickly shaped NuVasive into a global spine systems innovator, delivering highly differentiated technologies and procedurally integrated solutions to the market, improving patient outcomes by enabling better clinical decision-making and execution,” Don Rosenberg, lead independent director of NuVasive’s board, said in a news release. “We look forward to continuing to work with Greg, leveraging his business leadership and industry expertise as chairman of the Board.”
NuVasive (Nasdaq: NUVA) nabbed a high-ranking executive from its competitor to serve as its new CEO. Christopher Barry, who leads the Medtronic’s second-largest business unit as president of surgical innovations, will begin his new role with NuVasive on Nov. 5. He will also join the company’s board of directors.
In his current role, Barry oversees $5.5 billion in annual revenue and leads 14,000 employees across 78 countries. Rosenberg said the board selected Barry during their recruitment efforts for his expertise in the medical device industry and his reputation as a strategic leader.
“Chris has successfully led teams globally, managed complex R&D programs, driven commercial initiatives and executed strategic acquisitions. He has built a stellar reputation for driving employee engagement and operational excellence,” Lucier said in a news release. “As a Board member and shareholder, I have every confidence in Chris’s ability to take NuVasive to its next level of growth.”
NuVasive made one additional promotion with the Oct. 19 announcement. Matt Link, executive vice president for strategy, technology and corporate development, was promoted to president of the company. He has worked with NuVasive since 2006.